Video

AUA 2022 Bladder Cancer Forum VL

Search

Optimizing BCG Therapy in Bladder Cancer: Expert Insights on Managing Toxicity and Maximizing Efficacy - Badrinath Konety & Wassim Kassouf Details Badrinath Konety and Wassim Kassouf discuss managing Bacillus Calmette–Guérin (BCG) toxicity and optimizing BCG therapy in bladder cancer with Wei Shen Tan. BCG toxicity can range from local bladder symptoms to systemic effects. Patient selection is crucial in reducing toxicity, avoiding BCG in cases of gross hematuria or symptomatic UTIs. Delaying BCG and using longer intervals between instillati...
Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley Details Alicia Morgans and Patrick Hensley dive into the complexities surrounding the timing of cystectomy in BCG-unresponsive bladder cancer patients. Dr. Hensley emphasizes the need for a risk-stratified approach, particularly in identifying patients on the BCG failure spectrum, as these patients often present with worse outcomes. Dr. Hensley explains that high-risk patients should receive standard-of-c...
The Controversy Over Radical Cystectomy for N1 and N2 Bladder Cancer: Experts Weigh In - Brant Inman & Yair Lotan Details Kamal Pohar moderates a conversation with Brant Inman and Yair Lotan. The experts delve into the role of radical cystectomy for clinical N1 or N2 bladder cancer. Dr. Inman advocates for cystectomy combined with lymph adenectomy after systemic therapy, emphasizing its potential for better patient outcomes. Dr. Lotan, however, raises concerns about the heterogeneity in node positivity and the limita...
The Impact of Variant Histology on the Management of Patients with Bladder Cancer - Mario Fernandez and Michael A. O’Donnell Details Michael O’Donnell and Mario Fernandez join Peter Black to discuss the impact of variant histology on managing patients with bladder cancer. The conversation begins with deciding when the evidence supports preserving the bladder vs. performing a cystectomy. Then the discussion moves to other treatment options, including how the BCG shortage has led to new treatment alternatives for micropapillary b...
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta Details In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...
Do We Need to Perform Radical Cystectomy for Patients Who are cT0 After Neoadjuvant Chemotherapy? - Gary Steinberg & John Taylor Details The 2022 Annual Meeting of the American Urological Association (AUA) was host to The International Bladder Cancer Group (IBCG) AUA Bladder Cancer Forum which featured a case-based debate regarding the role of radical cystectomy in a patient who achieves a cT0 status after neoadjuvant chemotherapy. Drs. Gary Steinberg and John Taylor join Patrick Hensley providing highlights from their side of the...